Novartis AG stock (CH0012005267): solid Q1 momentum keeps big pharma name in focus

Novartis AG pleased investors with higher sales and profit in the first quarter of 2026 and confirmed its outlook, while the share remains a heavyweight in global healthcare portfolios – also for US investors via its NYSE listing.

Novartis AG began 2026 with a solid set of first-quarter figures and reiterated its full-year guidance, keeping the Swiss pharma group on the radar of global equity investors, according to a quarterly update published on 04/23/2026 by the company and subsequent coverage from financial media on the same day Novartis investors as of 04/23/2026.

On the US market, the American depositary receipts of Novartis traded around 150 USD on the New York Stock Exchange on 05/20/2026, according to recent price data compiled by MarketBeat MarketBeat as of 05/20/2026.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals, healthcare
• Headquarters/country: Basel, Switzerland
• Core markets: Global focus with strong presence in the US, Europe and Asia
• Key revenue drivers: Innovative prescription medicines in cardiovascular, immunology, neuroscience and oncology
• Home exchange/listing venue: SIX Swiss Exchange and NYSE (ticker: NVS)
• Trading currency: Swiss franc on SIX, US dollar on NYSE

Novartis AG: core business model

Novartis focuses on prescription medicines based on patented active ingredients, targeting chronic and severe diseases where medical need is high. The group concentrates on innovation-driven therapies rather than generic drugs, which it separated in 2023 by spinning off Sandoz, according to company information published with its 2023 annual report on 01/31/2024 Novartis media release as of 01/31/2024.

The strategy is built around a focused portfolio of high-value medicines, including blockbuster products in cardiovascular, immunology, neuroscience and oncology. Management aims for growth in both volume and price by expanding indications and launching new products, while also investing heavily in research and development to replenish the pipeline, as highlighted in the group’s strategic update released on 09/05/2023 Novartis strategy update as of 09/05/2023.

Revenue streams are diversified across therapeutic areas and geographies, but a meaningful share comes from the United States, where pricing power and adoption of innovative drugs can be significant. This global footprint, combined with a pipeline of late-stage assets, positions the company as a major player in worldwide healthcare spending, which many portfolio managers view as a defensive segment during periods of macroeconomic uncertainty.

Main revenue and product drivers for Novartis AG

In the first quarter of 2026, Novartis reported higher net sales and core operating income, supported by key products such as heart-failure therapy Entresto and immunology drug Cosentyx, according to its Q1 2026 earnings release dated 04/23/2026 Novartis Q1 2026 results as of 04/23/2026.

Management confirmed its outlook for 2026, expecting a further increase in group net sales and core operating income at constant currencies. This guidance suggests that the company sees continued demand for its leading therapies and anticipates contributions from newer launches in cardiovascular and oncology indications, as described in the same Q1 2026 communication Novartis Q1 2026 results as of 04/23/2026.

Beyond established brands, Novartis also invests in gene and cell therapies and in targeted cancer treatments, areas that may offer higher growth but often come with greater development risk and regulatory complexity. For US investors following large-cap pharma, this blend of mature blockbusters and emerging technologies can be a central part of the investment case, especially in diversified healthcare or global equity portfolios.

Why Novartis AG matters for US investors

Novartis trades in the United States via American depositary receipts under the ticker NVS on the NYSE, giving US-based investors straightforward access without using foreign broker routes. The stock is also a notable component of several international and ex-US equity exchange-traded funds, including broad products that track global developed markets, based on portfolio data from major ETF providers as of 04/30/2026 Schwab ETF research as of 04/30/2026.

As one of Europe’s largest pharma groups by market capitalization, Novartis offers exposure to global healthcare trends such as aging populations, expanded access to treatments in emerging markets and rising spending on chronic disease management. For US investors seeking diversification beyond domestic pharma giants, the company provides non-US currency exposure and a slightly different regulatory environment, while still reporting in a format that is widely followed by Wall Street analysts.

Dividend payments also play a traditional role in the Novartis equity story. The company typically pays an annual dividend in Swiss francs following its general meeting; for the 2024 financial year, shareholders approved a higher payout according to the results of the annual general meeting published on 03/05/2025 Novartis AGM 2025 results as of 03/05/2025.

Conclusion

Novartis AG enters 2026 with improving earnings metrics, a reaffirmed outlook and a focused portfolio of patented medicines, which together help to support its role as a core holding in many global healthcare strategies. The NYSE-listed shares offer US investors direct exposure to a major European pharma name, combining defensive characteristics with pipeline-related opportunities and risks. As always with large-cap pharmaceuticals, future performance will depend on clinical-trial outcomes, regulatory decisions, competitive dynamics and pricing environments across key markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.